Subscribe
shutterstock_1277801254_hafakot
hafakot / Shutterstock.com
1 March 2021BiotechnologyAlex Baldwin

Cutting back the thickets of Biosimilars

The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act (BPCIA) in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Biosimilar boom could save billions, think tank claims
25 October 2017   Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.
Americas
Amgen and Daiichi Sankyo ink biosimilar agreement
15 July 2016   Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.


Editor's picks

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025

Editor's picks

Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

More on this story

Americas
Biosimilar boom could save billions, think tank claims
25 October 2017   Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.
Americas
Amgen and Daiichi Sankyo ink biosimilar agreement
15 July 2016   Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.

More on this story

Americas
Biosimilar boom could save billions, think tank claims
25 October 2017   Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.
Americas
Amgen and Daiichi Sankyo ink biosimilar agreement
15 July 2016   Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.

More features

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland